These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22623231)

  • 1. [Omega-3--clopidogrel can help!].
    Huczek Z
    Kardiol Pol; 2012; 70(5):446. PubMed ID: 22623231
    [No Abstract]   [Full Text] [Related]  

  • 2. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
    Gajos G; Zalewski J; Nessler J; Zmudka K; Undas A; Piwowarska W
    Kardiol Pol; 2012; 70(5):439-45. PubMed ID: 22623230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel resistance - a clear problem with an unclear solution.
    Bansilal S; Bhatt DL
    Indian Heart J; 2012; 64(4):353-5. PubMed ID: 22929816
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
    Tousoulis D; Siasos G; Zaromitidou M; Oikonomou E; Maniatis K; Kioufis S; Kokkou E; Papavassiliou AG; Stefanadis C
    Int J Cardiol; 2013 Sep; 168(2):1594-6. PubMed ID: 23402725
    [No Abstract]   [Full Text] [Related]  

  • 5. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?
    Bhatt DL
    JAMA; 2009 Aug; 302(8):896-7. PubMed ID: 19706866
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
    Jang JS; Cho KI; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Seol SH; Kim DI; Kim BH; Park YH; Je HG; Jeong YH; Lee SW
    Am J Cardiol; 2012 Aug; 110(4):502-8. PubMed ID: 22591668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.
    Lee JM; Park S; Shin DJ; Choi D; Shim CY; Ko YG; Kim JS; Shin ES; Chang CW; Lee JE; Jang Y
    Am J Cardiol; 2009 Jul; 104(1):46-51. PubMed ID: 19576320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variability in response to clopidogrel therapy and its clinical implications.
    Yukhanyan L; Freynhofer MK; Siller-Matula J; Schrör K; Huber K
    Thromb Haemost; 2011 May; 105 Suppl 1():S55-9. PubMed ID: 21479337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
    Zabalza M; Subirana I; Sala J; Lluis-Ganella C; Lucas G; Tomás M; Masiá R; Marrugat J; Brugada R; Elosua R
    Heart; 2012 Jan; 98(2):100-8. PubMed ID: 21693476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

  • 12. Clopidogrel in acute coronary syndrome: to genotype or not?
    Storey RF
    Lancet; 2009 Jan; 373(9660):276-8. PubMed ID: 19108882
    [No Abstract]   [Full Text] [Related]  

  • 13. Current status of clopidogrel pharmacogenomics.
    Giusti B; Gori AM; Marcucci R; Abbate R
    Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.
    Liu XL; Wang ZJ; Yang Q; Ge HL; Gao F; Liu YY; Shi DM; Zhao YX; Zhou YJ
    Chin Med J (Engl); 2010 Nov; 123(22):3178-83. PubMed ID: 21163112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 16. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putting genomics into practice.
    Holmes MV; Casas JP; Hingorani AD
    BMJ; 2011 Aug; 343():d4953. PubMed ID: 21816737
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Bhattacharyya S; Rakhit R
    Lancet; 2009 Apr; 373(9670):1171; author reply 1172-3. PubMed ID: 19345825
    [No Abstract]   [Full Text] [Related]  

  • 20. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.
    Steinhubl SR
    Circulation; 2010 Feb; 121(4):481-3. PubMed ID: 20083686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.